AI assistant
ALGORAE PHARMACEUTICALS LIMITED — Capital/Financing Update 2016
Nov 23, 2016
64249_rns_2016-11-23_1a8d7f09-1999-4710-8db5-f068a960cf55.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [333 x 175] intentionally omitted <==
MARKET RELEASE
24 November 2016
Living Cell Technologies Limited
TRADING HALT
The securities of Living Cell Technologies Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Monday, 28 November 2016 or when the announcement is released to the market.
Security Code: LCT
Andia Petropoulos Adviser, Listings Compliance (Sydney)
==> picture [99 x 58] intentionally omitted <==
Living Cell Technologies Limited
ACN: 104 028 042 ASX: LCT OTCQX: LVCLY
24 November 2016
Ms Andia Petropoulos Adviser ASX Compliance 20 Bridge Street Sydney NSW 2000
Email: [email protected]
Dear Ms Petropoulos,
Trading Halt Request
Pursuant to ASX Listing Rule 17.1, Living Cell Technologies Limited (“LCT”) seeks a trading halt with immediate effect pending a capital raising through Hunter Capital Advisors.
The proposed trading halt is expected to last until the earlier of the commencement of trading on Monday, 28 November 2016 or the release of an announcement to ASX. LCT is not aware of any reason why the trading halt should not be granted.
If you would like more information, please email Stephen Silver of Hunter Capital Advisors at [email protected]
Yours sincerely,
==> picture [195 x 65] intentionally omitted <==
Mark Licciardo Company Secretary